Profil
Mark G.
Fromhold is currently the VP-Manufacturing & Business Development at Koronis Pharmaceuticals, Inc. He previously worked as a Research Scientist at Chiron Corp.
and as a Senior CMC Project Manager at ICOS Corp.
Dr. Fromhold completed his undergraduate degree at Hope College and his graduate and doctorate degrees at Indiana University.
Aktive Positionen von Mark G. Fromhold
| Unternehmen | Position | Beginn |
|---|---|---|
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops antiviral therapeutics based on viral decay acceleration | Corporate Officer/Principal | 01.02.2011 |
Ehemalige bekannte Positionen von Mark G. Fromhold
| Unternehmen | Position | Ende |
|---|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Technik-/Wissenschafts-/F&E-Leiter | - |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology Manufactures medications to treat inflammation and other serious diseases | Corporate Officer/Principal | - |
Ausbildung von Mark G. Fromhold
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology Manufactures medications to treat inflammation and other serious diseases | Health Technology |
Hope College
Hope College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops antiviral therapeutics based on viral decay acceleration | Health Technology |
















